

Product Data Sheet

Product Name: UBX1325

Cat. No.: GC71119

Chemical Properties

Cas. No. 2271269-01-1

Formula $C_{53}H_{59}ClF_3N_6O_{10}PS_3$ M.Wt 1159.69


Solubility DMSO : 100 mg/mL (86.23 mM);
Need ultrasonic; Hygroscopic DMSO
has a significant impact on the
solubility of product, please use
newly opened DMSO)

Storage -20°C, sealed storage, away from
moisture

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the
ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or
blue ice upon request.

Structure



Background

UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

UBX1325 leads to a decrease in the anti-apoptotic Bcl-xL:Bim complex in retina by intravitreal (IVT) injection administration in oxygen induced retinopathy (OIR) C57BL/6 mice model^[1].
UBX1325 can cause a decrease in retinal vascular permeability and promote retinal neovascularization in streptozotocin (STZ)-induced retinopathy mice model^[1].

References:

[1]. Pamela Tsuruda, et al. UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy. Investigative Ophthalmology & Visual Science June 2021, Volume 62, Issue 8

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA